Aptevo Therapeutics (APVO) Competitors $4.38 -0.08 (-1.79%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$4.37 -0.01 (-0.21%) As of 01/31/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APVO vs. ADXN, HOTH, BLRX, BFRI, RDHL, OBSV, CYCN, ORGS, EVAX, and ABVCShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Addex Therapeutics (ADXN), Hoth Therapeutics (HOTH), BioLineRx (BLRX), Biofrontera (BFRI), RedHill Biopharma (RDHL), ObsEva (OBSV), Cyclerion Therapeutics (CYCN), Orgenesis (ORGS), Evaxion Biotech A/S (EVAX), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Addex Therapeutics Hoth Therapeutics BioLineRx Biofrontera RedHill Biopharma ObsEva Cyclerion Therapeutics Orgenesis Evaxion Biotech A/S ABVC BioPharma Aptevo Therapeutics (NASDAQ:APVO) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends. Is APVO or ADXN more profitable? Addex Therapeutics has a net margin of 850.30% compared to Aptevo Therapeutics' net margin of 0.00%. Addex Therapeutics' return on equity of -112.43% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -353.04% -132.42% Addex Therapeutics 850.30%-112.43%-77.95% Which has preferable earnings & valuation, APVO or ADXN? Addex Therapeutics has lower revenue, but higher earnings than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo Therapeutics$3.11M0.72-$17.41MN/AN/AAddex Therapeutics$1.83M4.46-$11.76M-$0.34-22.65 Which has more volatility and risk, APVO or ADXN? Aptevo Therapeutics has a beta of 5.11, suggesting that its stock price is 411% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Does the MarketBeat Community prefer APVO or ADXN? Aptevo Therapeutics received 184 more outperform votes than Addex Therapeutics when rated by MarketBeat users. However, 51.72% of users gave Addex Therapeutics an outperform vote while only 50.13% of users gave Aptevo Therapeutics an outperform vote. CompanyUnderperformOutperformAptevo TherapeuticsOutperform Votes19950.13% Underperform Votes19849.87% Addex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Do analysts rate APVO or ADXN? Aptevo Therapeutics currently has a consensus target price of $10,952.00, indicating a potential upside of 249,945.66%. Addex Therapeutics has a consensus target price of $30.00, indicating a potential upside of 289.61%. Given Aptevo Therapeutics' higher possible upside, equities research analysts clearly believe Aptevo Therapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to APVO or ADXN? In the previous week, Aptevo Therapeutics had 3 more articles in the media than Addex Therapeutics. MarketBeat recorded 4 mentions for Aptevo Therapeutics and 1 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 1.89 beat Aptevo Therapeutics' score of 0.47 indicating that Addex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aptevo Therapeutics Neutral Addex Therapeutics Very Positive Do institutionals and insiders hold more shares of APVO or ADXN? 8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryAddex Therapeutics beats Aptevo Therapeutics on 9 of the 14 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.23M$6.86B$5.56B$9.11BDividend YieldN/A2.90%5.31%3.98%P/E RatioN/A9.9789.9918.25Price / Sales0.72227.221,221.9274.93Price / CashN/A73.5045.9637.70Price / Book0.005.275.124.71Net Income-$17.41M$136.98M$111.09M$224.24M7 Day Performance-7.20%-0.62%2.38%1.08%1 Month Performance1.62%0.15%3.20%1.51%1 Year Performance-99.95%7.68%24.70%20.44% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.5396 of 5 stars$4.38-1.8%$10,952.00+249,945.7%-100.0%$2.23M$3.11M0.0050Short Interest ↓ADXNAddex Therapeutics3.0523 of 5 stars$8.53+0.7%$30.00+251.7%-29.0%$9.04M$1.83M-25.0930HOTHHoth Therapeutics2.699 of 5 stars$1.22-10.3%$4.00+227.9%-8.7%$8.42MN/A-0.924Short Interest ↑Gap DownBLRXBioLineRx2.124 of 5 stars$0.11-3.9%$9.00+8,471.4%-92.5%$8.39M$4.80M-0.4840Short Interest ↑News CoverageGap DownBFRIBiofrontera2.5738 of 5 stars$1.04-4.6%$7.00+573.1%-15.0%$8.06M$34.07M-0.4670Short Interest ↓RDHLRedHill Biopharma0.6601 of 5 stars$6.23-3.3%N/A-98.4%$7.97M$6.53M0.00210Analyst ForecastShort Interest ↑News CoverageGap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Gap UpCYCNCyclerion Therapeutics2.6884 of 5 stars$2.71+1.1%N/A+30.7%$7.34M$1.62M0.0030Positive NewsGap UpORGSOrgenesisN/A$1.52+3.4%N/AN/A$7.30M$530,000.000.00150News CoverageEVAXEvaxion Biotech A/S2.9145 of 5 stars$6.00-0.5%$55.00+816.7%-87.5%$7.02M$70,000.00-4.1460Short Interest ↓News CoverageGap DownABVCABVC BioPharma1.4234 of 5 stars$0.54+2.9%N/A-66.0%$7.00M$150,000.00-0.6330Short Interest ↓News Coverage Related Companies and Tools Related Companies ADXN Alternatives HOTH Alternatives BLRX Alternatives BFRI Alternatives RDHL Alternatives OBSV Alternatives CYCN Alternatives ORGS Alternatives EVAX Alternatives ABVC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APVO) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredIs this the pin that pops the bubble? CEO Jensen Huang does not want you knowing this dirty little secret about Nvidia… In fact, any day now we’r...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | SponsoredThe #1 Stock for Trump’s First 100 DaysLegendary investor Louis Navellier believes this is just the beginning of Trump's 100-day melt-up. You shou...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.